Use of Rosuvastatin to Achieve Lipid Targets in African American Subjects With Cerebrovascular Disease
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- LDL value
研究概览
简要总结
This study will assess the rate at which rosuvastatin will achieve LDL targets in African American patients with previous history of stroke or TIA.
详细描述
Background:
Blacks have twice the risk of stroke compared to Whites and a recent analysis found that stroke incidence was decreasing in Whites but not Blacks. Identifying new avenues for stroke prevention is important in African Americans.
The Stroke Prevention through Aggressive Reduction of Cholesterol Levels (SPARCL) trial showed that treatment with atorvastatin 80 mg/d reduced the frequency of stroke by 16%. In the SPARCL trial, the mean low density lipoprotein-cholesterol (LDL-C in the treatment group was 73 mg/dl. On the basis of the SPARCL trial, the American Stroke Association now recommends statins with "intensive lipid lowering effects" for secondary prevention in the 2008 guideline update. Achieving target levels is most important for secondary prevention of stroke, when patients have an annual risk of stroke recurrence of 3-15% per year. Rosuvastatin is well suited for these secondary prevention goals due to its potent lipid-lowering effects.
Objectives
The objectives of this study are to establish the following:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 30 and above
- •Rankin score of ≤ 3
- •Patient has a fixed telephone number and is available for follow-up
- •African American
- •Diagnosis of ischemic stroke or TIA in past 12 months
排除标准
- •Liver enzyme abnormalities (ALT or AST >2x ULN)
- •Known muscle disorder or CK > 5x ULN
- •Alcoholism or substance abuse
- •Stroke due to dissection or hypercoagulable state
- •Moderate to severe dementia (MMSE <20)
- •On hemodialysis
- •No fixed home address
研究组 & 干预措施
Rosuvastatin
Patients that receive rosuvastatin
干预措施: Rosuvastatin (Drug)
结局指标
主要结局
LDL value
时间窗: three months
LDL value recorded three months after study entry
次要结局
未报告次要终点
研究者
Seemant Chaturvedi
Professor of Neurology
Wayne State University